این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
چهارشنبه 19 آذر 1404
Iranian Journal of Public Health
، جلد ۵۳، شماره ۸، صفحات ۱۷۵۴-۱۷۶۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Effect on Non-Small Cell Lung Cancer After Combination of Driver Gene Mutations and Anti-PD -1/PD-L1 Immunotherapy as Well as Chemotherapy
چکیده انگلیسی مقاله
Background: We aimed to reveal the correlation between pathological indicators and PD-L1, between gene mutation status in lung cancer through clinico-pathological data and lung cancer-related gene mutation and PD-L1 expression analysis. Methods: The study was conducted in . PD-L1 testing and targeted gene mutations detection were evaluated. The clinical characteristics of these non-small cell lung cancer (NSCLC) samples have been obtained. The groups were grouped according to clinico-pathological features and PD-L1 expression (Yes/No or High/Low), and the clinico-pathological and genetic and molecular features and correlation with PD-L1 expression were compared across the above groups. Comparisons and analyses were made between different treatment schemes. Results: Lung adenocarcinoma (LUAD, n=142) and lung squamous carcinoma (LUSC, n=143) samples were enrolled (median age: 64 years old). Pleural invasion and M staging were significantly different from PD-L1 alterations (P<0.05). The percentage of patients with PD-L1 tumor proportion score (TPS)≥50% was 36.24% and the percentage of patients with PD-L1 TPS<50% was 29.53%. The percentage of patients with PD-L1 high-expressed and treated by immunotherapy was 75.93% and 63.41% experienced Partial Response/Complete Response. The mutations ratio of EGFR, ALK, KRAS, MET, RET and TP53 were 28.86%, 1.34%, 6.04%, 0.67%, 1.34% and 0.67%, respectively. KRAS mutation was significantly different from PD-L1 alterations (P<0.01). Conclusion: There are individual differences in PD-L1 expression, which can also vary depending on the different clinical features. Specific molecular features correlate with differential PD-L1 expression and may influence the response to therapy.
کلیدواژههای انگلیسی مقاله
نویسندگان مقاله
| Zhengming Huang
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Long Yu
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Weisong Chen
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Dan Zhu
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
| Hui Chen
Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Zhejiang University, Zhejiang, China
نشانی اینترنتی
https://ijph.tums.ac.ir/index.php/ijph/article/view/33366
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات